Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. Antineoplaston A10 has been used in trials studying the treatment of glioma, sarcoma, lymphoma, lung cancer, liver cancer, and kidney cancer, among others.

UK-390957 is a selective serotonin reuptake inhibitor (SSRI) that was in phase II/III development in the USA, European Union and other territories with Pfizer, for the treatment of Premature ejaculation. UK-390957 represented a major development in sexual medicine, and offered patients the convenience of on-demand dosing, significant improvements in IELT, ejaculatory control, and sexual satisfaction with minimal adverse effects. However development of UK-390957 was discontinued.

Cyclindole is a tryptamine derivative in which the aminoethyl side-chain has been cyclized. Clinical trials of the drug have demonstrated antidepressant activity. The drug also possesses neuroleptic properties and acts as an antagonist of the D2 receptor.

There is no information in the scientific papers related to the biological properties of risocaine (also known as n-propyl 4-aminobenzoate). However, exists mention, that it is used as a local anesthetic.

Parbendazole is a potent inhibitor of microtubule assembly that was studied as an anthelmintic agent. Information about the current use of this drug is not available.

Taglutimide is a norbornane derivative patented by Kwizda, F. Joh., Chemische Fabrik as the sedative-hypnotic compound. In preclinical studies, Taglutimide did not produce any toxic effects when administered orally to mice even at a very high dosage. Central-nervous depression was demonstrated by a reduction in spontaneous motor activity, potentiation of the central-depressant effect of pentobarbital, antagonism of the central-stimulant effect of amphetamine after oral administration and by narcotic activity after i.v. administration of the drug. Furthermore, oral administration of Taglutimide potentiated the analgesic action of morphine without being effective on its own.

Metazamide is an imidazolone derivative exerting analgesic properties. It affects glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes.

Norepinephrine hydrochloride, (±)- (DL-Norepinephrine Hydrochloride) is a vasoconstrictor, cardiac stimulant, α- and β-sympathomimetic agent. DL-Norepinephrine hydrochloride is an adrenergic drug. Norepinephrine is an endogenous catecholamine that is the neurotransmitter at sympathetic postganglionic fibers. It has potent beta1- and alpha-stimulating effects. In contrast to epinephrine, norepinephrine has only minor effects on beta2 receptors. The clinical effects of norepinephrine administration are mainly increased cardiac index and increased vascular (systemic and pulmonary) resistance. Several adult studies have suggested that norepinephrine is useful in increasing SVR in patients with hyperdynamic or vasodilatory septic shock that is not responsive to dopamine or epinephrine. Additionally, it can augment coronary blood flow by increasing systemic diastolic pressure, at the expense of increasing afterload.

Carzenide is an antispasmodic that has been used in the treatment of dysmenorrhoea. Currently Carzenide is an organic synthesis intermediate, used for synthetic drug.